AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Afternoon, and welcome to AbCellera's Q2 twenty twenty six Business Update Conference Call. My name is Jonathan, and I will facilitate the audio portion of today's interactive broadcast. After the prepared remarks, we will host a question and answer If you would like to ask a question, please press star, one to raise your hand. To withdraw your question, press star, one again. At this time, I would like to turn the call over to Trent Symart, AbCellera's Chief Legal and Compliance Officer. You may proceed. Thank you. Hello, everyone. Thank you for joining us for AbCellera's Second Quarter twenty twenty six Earnings Call. I'm Trent Steimart, AbCellera's Chief Legal and Compliance Officer Doctor. Carl Hansen, AbCellera's President and CEO and Andrew Booth, AbCellera's Chief Financial Officer are speaking on today's call. During this call, we may make statements about our strategic priorities and financial outlook based on our current expectations and in accordance with the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Our statements are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those described. Please review the risk factors section of our most recent Form 10 ks and subsequent 10 Q filings with the SEC for a more detailed discussion of these risks. AbCellera assumes no obligation to update any forward looking statements to reflect events or circumstances after today's date. Our presentation today, our earnings press release and our SEC filings are available on our Investor Relations website. The information we provide about our pipeline is intended for the investment community and is not promotional. As we transition to our prepared remarks, please note that ...